Contravisory Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Contravisory Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,072	Closed	-$428K	–	391
2022 Q1	$428K	Sell	4,072 -299	-7%	-$29.1K	0.12%	110
2021 Q4	$471K	Buy	4,371 +299	+7%	+$32.6K	0.13%	112
2021 Q3	$446K	Hold	4,072	–	–	0.14%	94
2021 Q2	$381K	Buy	4,072 +135	+3%	+$12.4K	0.11%	120
2021 Q1	$362K	Sell	3,937 -393	-9%	-$33.2K	0.11%	104
2020 Q4	$317K	Sell	4,330 -294	-6%	-$21.9K	0.1%	113
2020 Q3	$359K	Hold	4,624	–	–	0.12%	87
2020 Q2	$221K	Hold	4,624	–	–	0.08%	140
2020 Q1	$137K	Sell	4,624 -111	-2%	-$3.75K	0.06%	156
2019 Q4	$171K	Buy	+4,735	New	+$145K	0.06%	151
2018 Q1	–	Sell	-43	Closed	-$1K	–	500
2017 Q4	$1K	Hold	43	–	–	﹤0.01%	417
2017 Q3	$1K	Buy	+43	New	+$547	﹤0.01%	470

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Contravisory Investment Management's HZNP Position: Q2 2022 in Review

Contravisory Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 4,072 shares — an estimated $428K sold.

Contravisory Investment Management first reported a position in HZNP in Q3 2017 and held it in 12 quarters. The position peaked at $471K in Q4 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Contravisory Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Contravisory Investment Management sold 4,072 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $428K.
Contravisory Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2017 and held it in 12 quarters.
Contravisory Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $471K in Q4 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Contravisory Investment Management's 13F filing for Q2 2022, filed 13 Jul 2022.